Edwards Lifesciences Q2 Profit Down; Raises 2026 Sales Outlook

Edwards Lifesciences reported Q2 net income of $241.9M ($0.42/share), down from $333.2M ($0.56) last year, but adjusted EPS rose to $0.78 from $0.67. Revenue grew 13.6% to $1.74B, with TAVR sales up 11.3% to $1.26B and TMTT up 47.3% to $195.9M; operating margin improved to 29.5% (+270 bps). For 2026, the company raised constant-currency sales growth guidance to 10%–11% and lifted TAVR growth to 8%–9% while reaffirming adjusted EPS at $2.95–$3.05.

Analysis

EW is still behaving like a premium-quality compounder, but the important signal is not the headline growth rate — it is that the company can raise the top-line outlook while preserving high-20s operating margins. That suggests the franchise still has pricing power and hospital switching costs, which usually supports a premium multiple in medtech. The caveat is that unchanged EPS guidance despite better sales implies incremental revenue is not dropping straight to the bottom line, so investors should not over-earnings-leverage the model from here.

The competitive read-through is more interesting than the company-specific print. In structural heart, a vendor that can keep execution tight on both mature TAVR and the newer mitral/tricuspid franchise tends to lock in procedural standardization at hospitals, which raises the bar for Abbott and Medtronic to displace share. The second-order effect is that competitive pressure may shift from device differentiation to clinical education, inventory placement, and contracting — all slower-moving moats that favor the incumbent with the broadest installed base.

The market is likely to react positively near term, but the next 1-3 months will be about proving that TMTT is not just a high-growth niche but a real offset to TAVR maturation. The contrarian risk is that consensus may be underestimating how quickly the market will discount any flattening in TAVR or any sign that TMTT remains too small to move the overall growth needle. Falsifiers: a guide cut, margin stall below ~29%, or evidence that procedure momentum is decelerating faster than revenue converts.

Key Decisions for Investors

• Buy EW on a 2-4% post-earnings pullback; 3-6 month horizon with a stop if constant-currency growth falls back below 9% or adjusted operating margin slips under 29%.
• Pair trade: long EW / short MDT into the next structural-heart read-through; thesis is EW’s faster mix shift and better margin discipline versus a slower-moving competitor set, with a 1-3 month catalyst window.
• If already long EW, overwrite some upside with near-dated calls into strength only if valuation expands faster than guidance — the key risk is the market paying up before TMTT becomes large enough to matter at the consolidated level.